Stifel has reaffirmed its Buy rating and a $10.00 price target on Erasca Inc (NASDAQ:ERAS) after a fireside chat between the firm and Erasca’s CFO/CBO, David Chacko, at the 2026 Stifel Biotech Ski Summit held in Park City from February 2-4.
The broker noted several takeaways from the meeting, emphasizing Erasca’s standing within the pan-RAS competitive landscape. Stifel’s analyst, Laura Prendergast, said Erasca views Revolution Medicines as the first mover in the space, with Erasca positioning itself in second place following receipt of a COM (Certificate of Marketing) in October 2025.
Prendergast drew particular attention to Erasca’s ERAS-0015 candidate. According to the firm, the molecule is engineered to balance pharmacokinetics (PK) and potency, a design choice Erasca believes may offer an advantage over rivals that prioritize one attribute at the expense of the other and risk a less favorable therapeutic index.
At the same time, Erasca highlighted the technical and intellectual-property hurdles associated with developing pan-RAS inhibitors. Company representatives told Stifel that the tri-complex chemistry underpinning these agents, together with IP protections, makes them especially difficult to create, and that developing a pan-KRAS inhibitor is comparatively easier. Erasca credited WuXi for conducting the medicinal chemistry that led to the discovery of ERAS-0015.
Market activity has reflected heightened investor interest in the name. The stock is trading at $12.29, near its 52-week high of $12.47, and has generated strong short-term returns, with a 15.83% gain in the past week and a 777.86% increase over the last six months, according to InvestingPro data. Those moves place the share price well above Stifel’s stated $10.00 target.
Financially, Erasca remains unprofitable on a trailing-12-month basis, with a net loss of $127.69 million. The company does report a robust current ratio of 10.45, reflecting short-term liquidity. InvestingPro’s analysis, however, flags the shares as appearing overvalued relative to their Fair Value and notes the RSI indicates overbought conditions. InvestingPro also provides a set of 12 additional tips on the company’s finances and market position intended to help investors assess the stock’s elevated momentum.
On the funding front, Erasca completed a public offering of 25,875,000 shares of common stock at $10.00 per share, generating approximately $258.8 million in gross proceeds. That completed sale follows an earlier announcement of a proposed $150 million public offering of common stock which included a 30-day option for underwriters to buy an additional $22.5 million in shares; the terms of that proposed transaction were not finalized. Separately, Erasca reported preliminary, unaudited year-end cash and securities of about $341.8 million as of December 31, 2025, a figure that the company noted is subject to financial closing procedures.
Other sell-side responses to the company’s clinical and program updates were evident. Guggenheim raised its price target on Erasca to $12.00 from $5.00 while maintaining a Buy rating, citing updates on pan-RAS and pan-KRAS programs. H.C. Wainwright also lifted its target to $15.00 from $11.00 and kept a Buy rating after clinical information from the AURORAS-1 study of ERAS-0015 showed partial responses across multiple tumor types and RAS mutations. These moves reflect continued analyst interest in Erasca’s clinical-stage precision oncology efforts.
Stifel’s reiteration of the Buy rating and the discussion with management underline the firm’s view of Erasca’s competitive positioning in pan-RAS chemistry and the perceived technical advantages of ERAS-0015. At the same time, market measures indicate the stock is trading at a premium to several analyst valuations and remains a company with ongoing clinical and financial developments to monitor.